The estimated Net Worth of Hans Peter Hasler is at least $656 millier dollars as of 26 June 2019. Mr. Hasler owns over 10,000 units of Minerva Neurosciences Inc stock worth over $26,700 and over the last 18 years he sold NERV stock worth over $518,329. In addition, he makes $111,197 as Independent Director at Minerva Neurosciences Inc.
Hans has made over 10 trades of the Minerva Neurosciences Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of NERV stock worth $56,000 on 26 June 2019.
The largest trade he's ever made was exercising 108,750 units of Minerva Neurosciences Inc stock on 15 October 2007 worth over $5,788,763. On average, Hans trades about 5,892 units every 122 days since 2007. As of 26 June 2019 he still owns at least 10,000 units of Minerva Neurosciences Inc stock.
You can see the complete history of Mr. Hasler stock trades at the bottom of the page.
Hans Peter Hasler serves as Independent Director of the Company. Mr. Hasler has served on our Board since December 2017. Mr. Hasler is Founder and Chief Executive Officer of Vicarius Pharma AG, a privately held company that provides strategic options to non-European bio-pharma companies bringing late-stage assets to the European market. He is also Senior Advisor at SBTech Global Advisory. His prior experience includes Elan Corporation, where he was Chief Operating Officer, and Biogen, Inc., where his positions included Chief Operating Officer, Executive Vice President, Head of Global Neurology and International. Previously, Mr. Hasler was at Wyeth Pharmaceuticals as Senior Vice President, Chief Marketing Officer and Managing Director of Wyeth Group Germany and General Manager, Wyeth-Lederle Switzerland, Austria and ECE. Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland. Since September 2018, Mr. Hasler has been a director of Shield Therapeutics, an AIM-listed specialty-pharma company and since June 2009, he has served as a director of HBM Healthcare Investments, an investment company listed on SIX Swiss Exchange. Mr. Hasler holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich, Switzerland. Our Board believes Mr. Hasler’s experience helping bring late-stage assets to market, as well as his overall experience in the biotech industry in positions of leadership qualifies him to serve as a member of our Board.
As the Independent Director of Minerva Neurosciences Inc, the total compensation of Hans Hasler at Minerva Neurosciences Inc is $111,197. There are 12 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of $2,842,430.
Hans Hasler is 64, he's been the Independent Director of Minerva Neurosciences Inc since 2017. There are 5 older and 15 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.
Hans's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... et Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: